The burden of COPD in the U.S.A.

Results from the Confronting COPD survey

Michael Halpern, R. H. Stanford, R. Borker

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation that is not fully reversible, with disabling symptoms including chronic cough and dyspnoea. Although a number of studies in the U.S.A. have assessed the impact of COPD on the healthcare system and society, data on healthcare resource utilization (particularly outpatient services and medication use) in patients with mild to moderate COPD, or patients who meet symptom criteria for COPD but have not received this diagnosis, are limited or unavailable. To fill gaps in current knowledge about the impact of this disease, an economic analysis was conducted on the data collected from patients enrolled in the U.S.A. sample of Confronting COPD in North America and Europe, the first large-scale international survey of the burden of the disease. The annual cost of healthcare resource utilization was estimated at US$4119 per patient with COPD, with indirect (non-medical care) costs amounting to US$1527 per patient. The annual estimated societal cost was therefore US$5646 per patient. The majority of disease costs in the survey were associated with inpatient hospitalizations (US$2891). The results of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute exacerbations could substantially decrease the costs associated with this disease.

Original languageEnglish (US)
JournalRespiratory Medicine
Volume97
Issue numberSUPPL. C
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Chronic Obstructive Pulmonary Disease
Costs and Cost Analysis
Delivery of Health Care
Cost of Illness
Ambulatory Care
North America
Surveys and Questionnaires
Cough
Health Care Costs
Dyspnea
Inpatients
Hospitalization
Economics

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • Comorbidity
  • Direct costs
  • Hospitalization
  • Indirect costs
  • Survey
  • U.S.A.

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The burden of COPD in the U.S.A. Results from the Confronting COPD survey. / Halpern, Michael; Stanford, R. H.; Borker, R.

In: Respiratory Medicine, Vol. 97, No. SUPPL. C, 01.03.2003.

Research output: Contribution to journalArticle

@article{485f83d254aa4b3893d0da10aac661b3,
title = "The burden of COPD in the U.S.A.: Results from the Confronting COPD survey",
abstract = "Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation that is not fully reversible, with disabling symptoms including chronic cough and dyspnoea. Although a number of studies in the U.S.A. have assessed the impact of COPD on the healthcare system and society, data on healthcare resource utilization (particularly outpatient services and medication use) in patients with mild to moderate COPD, or patients who meet symptom criteria for COPD but have not received this diagnosis, are limited or unavailable. To fill gaps in current knowledge about the impact of this disease, an economic analysis was conducted on the data collected from patients enrolled in the U.S.A. sample of Confronting COPD in North America and Europe, the first large-scale international survey of the burden of the disease. The annual cost of healthcare resource utilization was estimated at US$4119 per patient with COPD, with indirect (non-medical care) costs amounting to US$1527 per patient. The annual estimated societal cost was therefore US$5646 per patient. The majority of disease costs in the survey were associated with inpatient hospitalizations (US$2891). The results of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute exacerbations could substantially decrease the costs associated with this disease.",
keywords = "Chronic obstructive pulmonary disease (COPD), Comorbidity, Direct costs, Hospitalization, Indirect costs, Survey, U.S.A.",
author = "Michael Halpern and Stanford, {R. H.} and R. Borker",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S0954-6111(03)80028-8",
language = "English (US)",
volume = "97",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. C",

}

TY - JOUR

T1 - The burden of COPD in the U.S.A.

T2 - Results from the Confronting COPD survey

AU - Halpern, Michael

AU - Stanford, R. H.

AU - Borker, R.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation that is not fully reversible, with disabling symptoms including chronic cough and dyspnoea. Although a number of studies in the U.S.A. have assessed the impact of COPD on the healthcare system and society, data on healthcare resource utilization (particularly outpatient services and medication use) in patients with mild to moderate COPD, or patients who meet symptom criteria for COPD but have not received this diagnosis, are limited or unavailable. To fill gaps in current knowledge about the impact of this disease, an economic analysis was conducted on the data collected from patients enrolled in the U.S.A. sample of Confronting COPD in North America and Europe, the first large-scale international survey of the burden of the disease. The annual cost of healthcare resource utilization was estimated at US$4119 per patient with COPD, with indirect (non-medical care) costs amounting to US$1527 per patient. The annual estimated societal cost was therefore US$5646 per patient. The majority of disease costs in the survey were associated with inpatient hospitalizations (US$2891). The results of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute exacerbations could substantially decrease the costs associated with this disease.

AB - Chronic obstructive pulmonary disease (COPD) is a progressive disorder of airflow limitation that is not fully reversible, with disabling symptoms including chronic cough and dyspnoea. Although a number of studies in the U.S.A. have assessed the impact of COPD on the healthcare system and society, data on healthcare resource utilization (particularly outpatient services and medication use) in patients with mild to moderate COPD, or patients who meet symptom criteria for COPD but have not received this diagnosis, are limited or unavailable. To fill gaps in current knowledge about the impact of this disease, an economic analysis was conducted on the data collected from patients enrolled in the U.S.A. sample of Confronting COPD in North America and Europe, the first large-scale international survey of the burden of the disease. The annual cost of healthcare resource utilization was estimated at US$4119 per patient with COPD, with indirect (non-medical care) costs amounting to US$1527 per patient. The annual estimated societal cost was therefore US$5646 per patient. The majority of disease costs in the survey were associated with inpatient hospitalizations (US$2891). The results of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute exacerbations could substantially decrease the costs associated with this disease.

KW - Chronic obstructive pulmonary disease (COPD)

KW - Comorbidity

KW - Direct costs

KW - Hospitalization

KW - Indirect costs

KW - Survey

KW - U.S.A.

UR - http://www.scopus.com/inward/record.url?scp=0037373003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037373003&partnerID=8YFLogxK

U2 - 10.1016/S0954-6111(03)80028-8

DO - 10.1016/S0954-6111(03)80028-8

M3 - Article

VL - 97

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - SUPPL. C

ER -